Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort

Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort

BackgroundDrug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ritonavir have been repurposed as treatments for COVID-19. Although lopinavir-ritonavir (LPV/r) and darunav...

Full description

Saved in:
Bibliographic Details
Main Authors: Dóra Paróczai, András Bikov, Andreea Blidaru, Emanuel Bobu, Ana Lascu, Cristian Ion Mot, Stefan Mihaicuta, Stefan Frent
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Cellular and Infection Microbiology
Subjects:
COVID-19
darunavir
lopinavir
propensity score matching
ritonavir
Online Access:https://www.frontiersin.org/articles/10.3389/fcimb.2024.1496176/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fcimb.2024.1496176/full

Similar Items